Australian Dollar: Neutral outlook inside tight range against US Dollar – UOB
United Overseas Bank (UOB) strategists Quek Ser Leang and Lee Sue Ann note that AUD/USD extended its recent gains on Tuesday, helped by improved risk appetite, but they still characterise the near-term move as only a tentative recovery. Intraday they look for the Australian Dollar (AUD) to edge higher within a narrow band, while over the coming 1–3 weeks they now hold a neutral stance, expecting sideways trade between nearby support and resistance.
Australian Dollar seen consolidating
"24-HOUR VIEW: After AUD closed 0.30% higher at 0.6972 yesterday, we highlighted the following yesterday: “The tentative increase in upward momentum is not sufficient to signal a sustained advance. Today, AUD is likely to edge higher, but it is likely to stay within a 0.6945/0.6985 range. In other words, AUD is unlikely to break clearly above 0.6985.” The subsequent price movements did not quite unfold as expected. AUD edged up to 0.6990 before settling at 0.6984 (+0.18%). The increase in upward momentum remains tentative. Today, we expect AUD to edge higher within a 0.6965/0.6995 range. "
"1-3 WEEKS VIEW: Following our negative AUD view from the middle of last month (see annotations in the chart below), we highlighted last Friday (02 Oct, spot at 0.6930) that “any further decline in AUD may fall short of the major support at 0.6866.” Yesterday (06 Oct, spot at 0.6970), we highlighted that “downward momentum is starting to slow, and a break above 0.6985 (no change in ‘strong resistance’ level) would indicate that 0.6866 is out of reach.” AUD then rose and broke above 0.6985 with a high of 0.6990. We are neutral on AUD now, and expect it to trade between 0.6935 and 0.7020."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly

XRP Ledger adds account control feature, enabling enterprises to manage assets offline.

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
